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Lung transplantation (LTx) is the only treatment available for adult and pediatric end-stage lung disease secondary to cystic fibrosis (CF).
The timing of introducing LTx has significant medical and psychological implications for the child and the family. This study explored the
views and recommendations of parents of children with CF, who had been asked to consider LTx and referred to a national transplant centre.
Parents participated in a telephone-based, semi-structured interview. Responses were analysed using Content Analysis. Parental
recommendations and the emergent protocol are discussed, together with implications for clinical practice.
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End-stage lung disease is the most common cause of
morbidity and mortality for patients with CF [1] for which
LTx has been available as a therapeutic option for children
and young people for over 15 years [2,3].
Recommending LTx for children with CF in the UK
depends on three factors [3]: (i) life expectancy of 2 years or
less, (ii) poor quality of life (QoL) and (iii) no contra-
indications. Life expectancy has been predicted using
statistical modeling of lung functioning in a number of
studies [4,5], with an FEV1 of 30% or lower remaining the
most important predictor of mortality and guideline for
referral [4].
For children and young people who meet the relevant
criteria, LTx is perhaps the only intervention that can
prolong life with quality. Cumulative international post-1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
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June 2002 are reported as being around 78% at 1 year and
49% at 5 years, the latter being lower for recipients aged
11–17 years-old [6].
The process of referral, listing and waiting is lengthy and
the psychosocial and physical stressors for patients and their
relatives, at all stages, are well-known [7]. There is evidence
that Fgetting the news and making the decision_ is
particularly traumatic, with 25% of young people [7], 14%
of fathers and 21% of mothers [8], demonstrating clinically
significant levels of distress. The task of the referring CF
centre is, therefore, to balance medical and psychological
considerations when raising the prospect of LTx. Early
referral gives children, young people and their families,
more time to assimilate complex information, to emotionally
come to terms with the issues and to make an informed
choice. It also allows the referring centre more time to
prepare and support the family. However, referring too early
may be unnecessarily psychologically distressing [9]. Late
referral can result in optimal care being compromised,
transplantation being deemed inappropriate (e.g. for venti-
lated patients), children being listed at their first visit with4 (2005) 259 – 262ed by Elsevier B.V. All rights reserved.
L. Lang et al. / Journal of Cystic Fibrosis 4 (2005) 259–262260limited time to discuss options or children dying before
receiving a donor offer.
This study explored the experiences of parents of
children with CF, in a regional pediatric CF centre, who
had been asked to consider LTx as a treatment choice and
subsequently referred to one of two national lung transplant
centres. The aim was to recruit their views on their actual
experience, of how the flow of information should be
managed, and how the process of initial introduction by the
referring centre could be improved.2. Method
2.1. Participants
10 families of children referred for LTx assessment were
asked to participate (the mean time between referral and
interview was 3 years and 4 months). Eight parents
participated (7 female; age-range 35–50 years; 7 married,
1 divorced). Children were aged between 3 and 16 years on
interview, all 8 having siblings (range 1–5).
2.2. Measures
A semi-structured interview was developed utilizing
established principles of interview format and question
construction [10]. The interview format was piloted with
feedback on form and content being incorporated, max-
imizing face and content validity.
2.3. Procedure
Participants were interviewed at home via telephone,
their responses being transcribed verbatim at the time.
Transcriptions were subjected to Content Analysis (CA), a
well-validated qualitative research tool [11]. Response
categories, consistent with recommended CA procedures
[10], were constructed to be exhaustive and Fmutually
exclusive_. Coding and category identification were under-
taken by two independent researchers, and then aggregated,
with 90% inter-rater agreement.3. Results
The results of the interview are summarized in Table 1.
The 2nd and 3rd columns represent parents’ actual experi-
ences and recommendations respectively. Examples of the
coding categories of parents’ responses are given in each
column. The final column provides the suggested protocol.
3.1. Distressing but facing reality
The majority of parents had no complaint about how LTx
was introduced. The experience was described as distressingand difficult to comprehend at the time. However, parents
felt discussion helped them face the reality of the situation.
Those who remained upset reported feeling that the team
had handled the situation poorly by inadequately preparing
or supporting them.
3.2. Gradual introduction and support by the CF team
A gradual and informal process of discussing CF and
treatment options prior to crisis-point was recommended as a
means of preparing and supporting families more effectively.
Having a good relationship with the clinician introducing
and discussing LTx was seen as essential. Parents felt the
process would also be less formal and less distressing if the
CF nurse, who knew the family and who had perhaps been
previously emotionally supportive, was central to this.
3.3. Availability of information
The majority of parents thought information was crucial
to preparation, suggesting various formats (e.g., written
material, videos, personal accounts, specific transplant
group meetings and counselling). Parents wanted informa-
tion at different times, either as soon as possible or when
LTx became an option for their child. Therefore, it seems
beneficial to have information available for parents to access
as and when they wish.
3.4. Bi-annual reviews when FEV1 deteriorates
All participants thought 6-monthly reviews of a child’s
overall functioning and condition were a positive step, when
FEV1 falls below 50% predicted; an initiative concurring
with the notion of gradually introducing LTx.
3.5. Referring for assessment
When the time for LTx referral arrived, parents wanted to
meet with the Consultant, the majority wanting to know all
the facts at this point in order to make a decision. Two of the
8 participants only wanted to know the positive aspects.
Several stated that following such discussions, they forgot
some of what was said and wanted written, bullet-point
information.
The majority of parents also wanted their partner/spouse
to be involved. Parents felt that their child’s age and ability
to understand and make their own decision were important
factors determining the extent to which their child was
involved initially.4. Discussion
This study utilized well-validated qualitative method-
ology in evaluating the experience of being introduced to
LTx in parents of children with CF from a single centre.
Table 1
Parental experiences and recommendations
Aspects of introduction Actual experience Recommendations Suggested protocol
When was LTx introduced Child very ill.1
‘‘Brought child home to die’’.
‘‘I expected them introducing it’’.
Prior to crisis point.
Introduce as soon as possible.
‘‘Constant, gradual informal process
of open discussion by CF nurse’’.
Need emotional support to deal with it.
Would rather avoid it.
Gradual introduction and support
early on by CF team.
Role of information Information helps prepare you.
‘‘I would have liked more information’’.
‘‘I didn’t want information,
I didn’t really want to deal with it’’.
‘‘Information makes you more aware and prepared’’.2
‘‘Having the information is depressing’’.
Information available to access as desired.
Role of bi-annual reviews Not applicable. Good idea.
Good idea, but with emphasis on everyday life,
rather than on medical aspects.
As child’s health deteriorates,
introduce bi-annual reviews.
Who introduced LTx Consultant only.3
Consultant + 1 team member.3
Consultant only.3
Consultant + 1 team member.3,4
‘‘Whole team too daunting’’.
Meet with the Consultant when need
to decide to place child on active list.
Family present No, only self.
Self & partner.
Self & child.
Self, partner & child.
Partner only.
Partner & child.
Partner present, child present depending
on age/ability to make own decisions.
Content of introducing LTx Child very ill, it’s a necessity.
It’s the next stage to consider.5
Child’s health deteriorating,
it’s the recommended option.5
‘‘I want to be told everything (e.g., assessment criteria,
procedures, complications and outcomes including statistics,
quality of life, drug side-effects and long-term prognosis)’’.
Only want to hear the positives.
In the meeting, give the facts and figures
and space/support to talk.
After meeting Not applicable. Written information to refer back to.5
Written info in bullet form or FAQs.5
Afterwards, written summary of facts
and decision-making discussion for parents.
1Child had recurrent chest infections, reduced lung capacity, difficulty breathing and antibiotics deemed not to be working; 2Parents wanted information either as soon as possible, or when LTx referral became an
option for their child; 3Parents, partner and/or affected child also present; 4Majority of parents suggested the presence of the CF nurse known to the family; 5Parents given the facts and time to talk/reflect.
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L. Lang et al. / Journal of Cystic Fibrosis 4 (2005) 259–262262Although the sample size is small, certain findings replicate
those found in a larger sample [12]. These were that parents
prefer to know about LTx prior to their child’s health
deteriorating (despite finding the issues anxiety-provoking),
want to talk face-to-face with their Consultant and want a
thorough explanation of the rationale and procedure.
However, in contrast to the previous work [12], parents in
this sample expressed the view that they would prefer the
CF nurse to begin the process of introducing LTx, rather
than the physician, and only wanted their child to be
involved at the appropriate time.
Although user-involvement studies need to be continu-
ous to develop Ffeedback loops_ for further service evalua-
tion and improvement, the present results, together with
previous findings [12,13], provide sufficient information to
guide pediatric CF teams when introducing LTx as a
treatment option. In summary these are:
& Introduction should be gradual with support available at
each Fstage_
& Information is highly valued and should be readily
available
& As FEV1 falls below 50% of predicted, 6-monthly
reviews should take place
& When LTx referral becomes imminent, meetings between
the family and their Consultant should take place
& Written summaries of initial discussions being provided
to aid retention of complex information.
In using these guidelines, it is important to re-evaluate
the experience of patients and their families on a regular
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